Palvella Therapeutics, Inc.
PVLA
$23.44
-$1.13-4.60%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.29M | 5.18M | 3.76M | 3.27M | 3.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.67M | 11.72M | 8.21M | 9.66M | 11.78M |
| Operating Income | -14.67M | -11.72M | -8.21M | -9.66M | -11.78M |
| Income Before Tax | -18.25M | 6.24M | 10.18M | 22.05M | 25.90M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.25 | 6.24 | 10.18 | 22.05 | 25.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.25M | 6.24M | 10.18M | 22.05M | 25.90M |
| EBIT | -14.67M | -11.72M | -8.21M | -9.66M | -11.78M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -2.91 | -1.50 | -0.81 | 0.27 | 0.89 |
| Normalized Basic EPS | -1.85 | -1.84 | -1.41 | -0.11 | 0.31 |
| EPS Diluted | -2.91 | -1.50 | -0.81 | 0.26 | 0.88 |
| Normalized Diluted EPS | -1.85 | -1.84 | -1.41 | -0.13 | 0.29 |
| Average Basic Shares Outstanding | 28.17M | 22.88M | 22.88M | 22.88M | 22.88M |
| Average Diluted Shares Outstanding | 28.17M | 22.88M | 22.88M | 23.00M | 23.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |